INVESTOR RELATIONS
TREATING NEUROINFLAMMATION
- Novel Resveratrol product that safely reaches therapeutic levels without GI side effects, creates treatment possibilities in many indications, including Alzheimer’s.
- The anti-inflammatory, oxidative-stress-reducing, and other mechanisms of action enable Jupiter’s flagship product, JOTROL™, to have multiple potential disease applications.
- Delivery platform allows for easy consumption in an easily consumable, oral soft gel in a patented micellar form.
STRATEGY
____________________
• To advance JOTROL™ through clinical development for the treatment of CNS diseases.
• To leverage data and literature reported on the capabilities of resveratrol as a therapeutic for numerous diseases.
• To examine JOTROL’s™ regulation of biological pathways to pursue indications in other disorders.
COMPETITIVE & CLINICAL ADVANTAGES
____________________
• Convenient route of administration: JOTROL™ is orally administered.
• Unique differentiator: unlike existing resveratrol formulations, JOTROL™ is highly bioavailable in plasma and in the brain.
• Promising evidence for clinical benefit: extensive evidence about JOTROL’s™ potential benefits for diseases, including Jupiter’s indications in the CNS.
• Excellent safety profile: no serious adverse effects.
• Large market opportunity: Alzheimer’s disease, $50B market; MPS-I, $150M market; Friedreich’s ataxia, $500M market; MELAS, $3B market.
